1. Salahuddin S. Z., Ablashi D. V., Markham P. D., Josephs S. F., Sturzenegger S., Kaplan M., Halligan G., Biberfeld P., Wong-Staal F., Kramarsky B., and et al. 1986. Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders Science. 234:596-601.
2. Ablashi D. V., Balachandran N., Josephs S. F., Hung C. L., Krueger G. R., Kramarsky B., Salahuddin S. Z., and Gallo R. C. 1991. Genomic polymorphism, growth properties, and immunologic variations in human herpesvirus-6 isolates Virology. 184:545-52.
3. Downing R. G., Sewankambo N., Serwadda D., Honess R., Crawford D., Jarrett R., and Griffin B. E. 1987. Isolation of human lymphotropic herpesviruses from Uganda Lancet. 2:390.
4. Gompels U. A., Nicholas J., Lawrence G., Jones M., Thomson B. J., Martin M. E., Efstathiou S., Craxton M., and Macaulay H. A. 1995. The DNA sequence of human herpesvirus-6: structure, coding content, and genome evolution Virology. 209:29-51.
5. Yamanishi K., Okuno T., Shiraki K., Takahashi M., Kondo T., Asano Y., and Kurata T. 1988. Identification of human herpesvirus-6 as a causal agent for exanthem subitum Lancet. 1:1065-7.
6. Lopez C., Pellett P., Stewart J., Goldsmith C., Sanderlin K., Black J., Warfield D., and Feorino P. 1988. Characteristics of human herpesvirus-6 J Infect Dis. 157:1271-3.
7. Dominguez G., Dambaugh T. R., Stamey F. R., Dewhurst S., Inoue N., and Pellett P. E. 1999. Human herpesvirus 6B genome sequence: coding content and comparison with human herpesvirus 6A J Virol. 73:8040-52.
8. Isegawa Y., Mukai T., Nakano K., Kagawa M., Chen J., Mori Y., Sunagawa T., Kawanishi K., Sashihara J., Hata A., Zou P., Kosuge H., and Yamanishi K. 1999. Comparison of the complete DNA sequences of human herpesvirus 6 variants A and B J Virol. 73:8053-63.
9. Ablashi D. V., Salahuddin S. Z., Josephs S. F., Imam F., Lusso P., Gallo R. C., Hung C., Lemp J., and Markham P. D. 1987. HBLV (or HHV-6) in human cell lines Nature. 329:207.
10. Chen M., Popescu N., Woodworth C., Berneman Z., Corbellino M., Lusso P., Ablashi D. V., and DiPaolo J. A. 1994. Human herpesvirus 6 infects cervical epithelial cells and transactivates human papillomavirus gene expression J Virol. 68:1173-8.
11. Luka J., Okano M., and Thiele G. 1990. Isolation of human herpesvirus-6 from clinical specimens using human fibroblast cultures J Clin Lab Anal. 4:483-6.
12. Simmons A., Demmrich Y., La Vista A., and Smith K. 1992. Replication of human herpesvirus 6 in epithelial cells in vitro J Infect Dis. 166:202-5.
13. Lusso P., Markham P. D., Tschachler E., di Marzo Veronese F., Salahuddin S. Z., Ablashi D. V., Pahwa S., Krohn K., and Gallo R. C. 1988. In vitro cellular tropism of human B-lymphotropic virus (human herpesvirus-6) J Exp Med. 167:1659-70.
14. Lusso P., Garzino-Demo A., Crowley R. W., and Malnati M. S. 1995. Infection of gamma/delta T lymphocytes by human herpesvirus 6: transcriptional induction of CD4 and susceptibility to HIV infection J Exp Med. 181:1303-10.
15. Lusso P., Malnati M. S., Garzino-Demo A., Crowley R. W., Long E. O., and Gallo R. C. 1993. Infection of natural killer cells by human herpesvirus 6 Nature. 362:458-62.
16. Kondo K., Kondo T., Okuno T., Takahashi M., and Yamanishi K. 1991. Latent human herpesvirus 6 infection of human monocytes/macrophages J Gen Virol. 72 ( Pt 6):1401-8.
17. Okuno T., Higashi K., Shiraki K., Yamanishi K., Takahashi M., Kokado Y., Ishibashi M., Takahara S., Sonoda T., Tanaka K., and et al. 1990. Human herpesvirus 6 infection in renal transplantation Transplantation. 49:519-22.
18. Fox J. D., Briggs M., Ward P. A., and Tedder R. S. 1990. Human herpesvirus 6 in salivary glands Lancet. 336:590-3.
19. Challoner P. B., Smith K. T., Parker J. D., MacLeod D. L., Coulter S. N., Rose T. M., Schultz E. R., Bennett J. L., Garber R. L., Chang M., and et al. 1995. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis Proc Natl Acad Sci U S A. 92:7440-4.
20. Luppi M., Barozzi P., Maiorana A., Marasca R., Trovato R., Fano R., Ceccherini-Nelli L., and Torelli G. 1995. Human herpesvirus-6: a survey of presence and distribution of genomic sequences in normal brain and neuroglial tumors J Med Virol. 47:105-11.
21. Yoshida M., Uno F., Bai Z. L., Yamada M., Nii S., Sata T., Kurata T., Yamanishi K., and Takahashi M. 1989. Electron microscopic study of a herpes-type virus isolated from an infant with exanthem subitum Microbiol Immunol. 33:147-54.
22. Biberfeld P., Kramarsky B., Salahuddin S. Z., and Gallo R. C. 1987. Ultrastructural characterization of a new human B lymphotropic DNA virus (human herpesvirus 6) isolated from patients with lymphoproliferative disease J Natl Cancer Inst. 79:933-41.
23. Clark D. A. 2000. Human herpesvirus 6 Rev Med Virol. 10:155-73.
24. Thomson B. J., Dewhurst S., and Gray D. 1994. Structure and heterogeneity of the a sequences of human herpesvirus 6 strain variants U1102 and Z29 and identification of human telomeric repeat sequences at the genomic termini J Virol. 68:3007-14.
25. Gompels U. A., and Macaulay H. A. 1995. Characterization of human telomeric repeat sequences from human herpesvirus 6 and relationship to replication J Gen Virol. 76 ( Pt 2):451-8.
26. Kishi M., Harada H., Takahashi M., Tanaka A., Hayashi M., Nonoyama M., Josephs S. F., Buchbinder A., Schachter F., Ablashi D. V., and et al. 1988. A repeat sequence, GGGTTA, is shared by DNA of human herpesvirus 6 and Marek's disease virus J Virol. 62:4824-7.
27. Luppi M., Marasca R., Barozzi P., Ferrari S., Ceccherini-Nelli L., Batoni G., Merelli E., and Torelli G. 1993. Three cases of human herpesvirus-6 latent infection: integration of viral genome in peripheral blood mononuclear cell DNA J Med Virol. 40:44-52.
28. Torelli G., Barozzi P., Marasca R., Cocconcelli P., Merelli E., Ceccherini-Nelli L., Ferrari S., and Luppi M. 1995. Targeted integration of human herpesvirus 6 in the p arm of chromosome 17 of human peripheral blood mononuclear cells in vivo J Med Virol. 46:178-88.
29. Morris C., Luppi M., McDonald M., Barozzi P., and Torelli G. 1999. Fine mapping of an apparently targeted latent human herpesvirus type 6 integration site in chromosome band 17p13.3 J Med Virol. 58:69-75.
30. Daibata M., Taguchi T., Taguchi H., and Miyoshi I. 1998. Integration of human herpesvirus 6 in a Burkitt's lymphoma cell line Br J Haematol. 102:1307-13.
31. Daibata M., Taguchi T., Nemoto Y., Taguchi H., and Miyoshi I. 1999. Inheritance of chromosomally integrated human herpesvirus 6 DNA Blood. 94:1545-9.
32. Santoro F., Kennedy P. E., Locatelli G., Malnati M. S., Berger E. A., and Lusso P. 1999. CD46 is a cellular receptor for human herpesvirus 6 Cell. 99:817-27.
33. Seya T., Hara T., Iwata K., Kuriyama S., Hasegawa T., Nagase Y., Miyagawa S., Matsumoto M., Hatanaka M., Atkinson J. P., and et al. 1995. Purification and functional properties of soluble forms of membrane cofactor protein (CD46) of complement: identification of forms increased in cancer patients' sera Int Immunol. 7:727-36.
34. Liszewski M. K., Post T. W., and Atkinson J. P. 1991. Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster Annu Rev Immunol. 9:431-55.
35. Mori Y., Yang X., Akkapaiboon P., Okuno T., and Yamanishi K. 2003. Human herpesvirus 6 variant A glycoprotein H-glycoprotein L-glycoprotein Q complex associates with human CD46 J Virol. 77:4992-9.
36. Mori Y., Akkapaiboon P., Yang X., and Yamanishi K. 2003. The human herpesvirus 6 U100 gene product is the third component of the gH-gL glycoprotein complex on the viral envelope J Virol. 77:2452-8.
37. Poffenberger K. L., and Roizman B. 1985. A noninverting genome of a viable herpes simplex virus 1: presence of head-to-tail linkages in packaged genomes and requirements for circularization after infection J Virol. 53:587-95.
38. Garber D. A., Beverley S. M., and Coen D. M. 1993. Demonstration of circularization of herpes simplex virus DNA following infection using pulsed field gel electrophoresis Virology. 197:459-62.
39. Mocarski E. S., and Roizman B. 1982. Structure and role of the herpes simplex virus DNA termini in inversion, circularization and generation of virion DNA Cell. 31:89-97.
40. Yao X. D., and Elias P. 2001. Recombination during early herpes simplex virus type 1 infection is mediated by cellular proteins J Biol Chem. 276:2905-13.
41. Dewhurst S., Dollard S. C., Pellett P. E., and Dambaugh T. R. 1993. Identification of a lytic-phase origin of DNA replication in human herpesvirus 6B strain Z29 J Virol. 67:7680-3.
42. Jacob R. J., Morse L. S., and Roizman B. 1979. Anatomy of herpes simplex virus DNA. XII. Accumulation of head-to-tail concatemers in nuclei of infected cells and their role in the generation of the four isomeric arrangements of viral DNA J Virol. 29:448-57.
43. Inoue N., Dambaugh T. R., Rapp J. C., and Pellett P. E. 1994. Alphaherpesvirus origin-binding protein homolog encoded by human herpesvirus 6B, a betaherpesvirus, binds to nucleotide sequences that are similar to ori regions of alphaherpesviruses J Virol. 68:4126-36.
44. Mirandola P., Menegazzi P., Merighi S., Ravaioli T., Cassai E., and Di Luca D. 1998. Temporal mapping of transcripts in herpesvirus 6 variants J Virol. 72:3837-44.
45. Yoshikawa T., Akimoto S., Nishimura N., Ozaki T., Ihira M., Ohashi M., Morooka M., Suga S., Asano Y., Takemoto M., and Nishiyama Y. 2003. Evaluation of active human herpesvirus 6 infection by reverse transcription-PCR J Med Virol. 70:267-72.
46. Mori Y., Yagi H., Shimamoto T., Isegawa Y., Sunagawa T., Inagi R., Kondo K., Tano Y., and Yamanishi K. 1998. Analysis of human herpesvirus 6 U3 gene, which is a positional homolog of human cytomegalovirus UL 24 gene Virology. 249:129-39.
47. Kashanchi F., Araujo J., Doniger J., Muralidhar S., Hoch R., Khleif S., Mendelson E., Thompson J., Azumi N., Brady J. N., Luppi M., Torelli G., and Rosenthal L. J. 1997. Human herpesvirus 6 (HHV-6) ORF-1 transactivating gene exhibits malignant transforming activity and its protein binds to p53 Oncogene. 14:359-67.
48. Kashanchi F., Thompson J., Sadaie M. R., Doniger J., Duvall J., Brady J. N., and Rosenthal L. J. 1994. Transcriptional activation of minimal HIV-1 promoter by ORF-1 protein expressed from the SalI-L fragment of human herpesvirus 6 Virology. 201:95-106.
49. Gravel A., Tomoiu A., Cloutier N., Gosselin J., and Flamand L. 2003. Characterization of the immediate-early 2 protein of human herpesvirus 6, a promiscuous transcriptional activator Virology. 308:340-53.
50. Rapp J. C., Krug L. T., Inoue N., Dambaugh T. R., and Pellett P. E. 2000. U94, the human herpesvirus 6 homolog of the parvovirus nonstructural gene, is highly conserved among isolates and is expressed at low mRNA levels as a spliced transcript Virology. 268:504-16.
51. Deiss L. P., Chou J., and Frenkel N. 1986. Functional domains within the a sequence involved in the cleavage-packaging of herpes simplex virus DNA J Virol. 59:605-18.
52. Black J. B., Sanderlin K. C., Goldsmith C. S., Gary H. E., Lopez C., and Pellett P. E. 1989. Growth properties of human herpesvirus-6 strain Z29 J Virol Methods. 26:133-45.
53. Cirone M., Campadelli-Fiume G., Foa-Tomasi L., Torrisi M. R., and Faggioni A. 1994. Human herpesvirus 6 envelope glycoproteins B and H-L complex are undetectable on the plasma membrane of infected lymphocytes AIDS Res Hum Retroviruses. 10:175-9.
54. Nii S., Yoshida M., Uno F., Kurata T., Ikuta K., and Yamanishi K. 1990. Replication of human herpesvirus 6 (HHV-6): morphological aspects Adv Exp Med Biol. 278:19-28.
55. Di Luca D., Katsafanas G., Schirmer E. C., Balachandran N., and Frenkel N. 1990. The replication of viral and cellular DNA in human herpesvirus 6-infected cells Virology. 175:199-210.
56. Balachandran N., Amelse R. E., Zhou W. W., and Chang C. K. 1989. Identification of proteins specific for human herpesvirus 6-infected human T cells J Virol. 63:2835-40.
57. Black J. B., Lopez C., and Pellett P. E. 1992. Induction of host cell protein synthesis by human herpesvirus 6 Virus Res. 22:13-23.
58. Aubin J. T., Poirel L., Agut H., Huraux J. M., Bignozzi C., Brossard Y., Mulliez N., Roume J., Lecuru F., and Taurelle R. 1992. Intrauterine transmission of human herpesvirus 6 Lancet. 340:482-3.
59. Hall C. B., Long C. E., Schnabel K. C., Caserta M. T., McIntyre K. M., Costanzo M. A., Knott A., Dewhurst S., Insel R. A., and Epstein L. G. 1994. Human herpesvirus-6 infection in children. A prospective study of complications and reactivation N Engl J Med. 331:432-8.
60. Kositanont U., Wasi C., Wanprapar N., Bowonkiratikachorn P., Chokephaibulkit K., Chearskul S., Chimabutra K., Sutthent R., Foongladda S., Inagi R., Kurata T., and Yamanishi K. 1999. Primary infection of human herpesvirus 6 in children with vertical infection of human immunodeficiency virus type 1 J Infect Dis. 180:50-5.
61. Yoshikawa T., Ihira M., Furukawa H., Suga S., Asonuma K., Tanaka K., and Asano Y. 1998. Four cases of human herpesvirus 6 variant B infection after pediatric liver transplantation Transplantation. 65:1266-9.
62. Yoshikawa T., Suga S., Asano Y., Yazaki T., Kodama H., and Ozaki T. 1989. Distribution of antibodies to a causative agent of exanthem subitum (human herpesvirus-6) in healthy individuals Pediatrics. 84:675-7.
63. Sobue R., Miyazaki H., Okamoto M., Hirano M., Yoshikawa T., Suga S., and Asano Y. 1991. Fulminant hepatitis in primary human herpesvirus-6 infection N Engl J Med. 324:1290.
64. Asano Y., Yoshikawa T., Suga S., Yazaki T., Kondo K., and Yamanishi K. 1990. Fatal fulminant hepatitis in an infant with human herpesvirus-6 infection Lancet. 335:862-3.
65. Rotola A., Ravaioli T., Gonelli A., Dewhurst S., Cassai E., and Di Luca D. 1998. U94 of human herpesvirus 6 is expressed in latently infected peripheral blood mononuclear cells and blocks viral gene expression in transformed lymphocytes in culture Proc Natl Acad Sci U S A. 95:13911-6.
66. Luppi M., Barozzi P., Morris C., Maiorana A., Garber R., Bonacorsi G., Donelli A., Marasca R., Tabilio A., and Torelli G. 1999. Human herpesvirus 6 latently infects early bone marrow progenitors in vivo J Virol. 73:754-9.
67. Krueger G. R., Wassermann K., De Clerck L. S., Stevens W. J., Bourgeois N., Ablashi D. V., Josephs S. F., and Balachandran N. 1990. Latent herpesvirus-6 in salivary and bronchial glands Lancet. 336:1255-6.
68. Hammerling J. A., Lambrecht R. S., Kehl K. S., and Carrigan D. R. 1996. Prevalence of human herpesvirus 6 in lung tissue from children with pneumonitis J Clin Pathol. 49:802-4.
69. Knox K. K., Pietryga D., Harrington D. J., Franciosi R., and Carrigan D. R. 1995. Progressive immunodeficiency and fatal pneumonitis associated with human herpesvirus 6 infection in an infant Clin Infect Dis. 20:406-13.
70. Reux I., Fillet A. M., Agut H., Katlama C., Hauw J. J., and LeHoang P. 1992. In situ detection of human herpesvirus 6 in retinitis associated with acquired immunodeficiency syndrome Am J Ophthalmol. 114:375-7.
71. Singh N., and Paterson D. L. 2000. Encephalitis caused by human herpesvirus-6 in transplant recipients: relevance of a novel neurotropic virus Transplantation. 69:2474-9.
72. Buchwald D., Cheney P. R., Peterson D. L., Henry B., Wormsley S. B., Geiger A., Ablashi D. V., Salahuddin S. Z., Saxinger C., Biddle R., and et al. 1992. A chronic illness characterized by fatigue, neurologic and immunologic disorders, and active human herpesvirus type 6 infection Ann Intern Med. 116:103-13.
73. Yalcin S., Kuratsune H., Yamaguchi K., Kitani T., and Yamanishi K. 1994. Prevalence of human herpesvirus 6 variants A and B in patients with chronic fatigue syndrome Microbiol Immunol. 38:587-90.
74. Goodman A. D., Mock D. J., Powers J. M., Baker J. V., and Blumberg B. M. 2003. Human herpesvirus 6 genome and antigen in acute multiple sclerosis lesions J Infect Dis. 187:1365-76.
75. Hallas C., Neipel F., Huettner C., Schreiner D., Fleckenstein B., and Muller-Hermelink H. K. 1996. Presence of human herpesvirus type 6 in sporadic lymphoproliferative disorders. A comparative study Diagn Mol Pathol. 5:166-72.
76. Sumiyoshi Y., Kikuchi M., Ohshima K., Takeshita M., Eizuru Y., and Minamishima Y. 1993. Analysis of human herpes virus-6 genomes in lymphoid malignancy in Japan J Clin Pathol. 46:1137-8.
77. Trovato R., Luppi M., Vago L., Torelli G., Moroni M., and Ceccherini-Nelli L. 1995. Frequency of human herpesvirus type 6 (HHV-6) genome detection in AIDS-related lymphoproliferative disorders J Acquir Immune Defic Syndr Hum Retrovirol. 9:311-2.
78. Di Luca D., Dolcetti R., Mirandola P., De Re V., Secchiero P., Carbone A., Boiocchi M., and Cassai E. 1994. Human herpesvirus 6: a survey of presence and variant distribution in normal peripheral lymphocytes and lymphoproliferative disorders J Infect Dis. 170:211-5.
79. Torelli G., Marasca R., Luppi M., Selleri L., Ferrari S., Narni F., Mariano M. T., Federico M., Ceccherini-Nelli L., Bendinelli M., and et al. 1991. Human herpesvirus-6 in human lymphomas: identification of specific sequences in Hodgkin's lymphomas by polymerase chain reaction Blood. 77:2251-8.
80. Ohyashiki J. H., Abe K., Ojima T., Wang P., Zhou C. F., Suzuki A., Ohyashiki K., and Yamamoto K. 1999. Quantification of human herpesvirus 6 in healthy volunteers and patients with lymphoproliferative disorders by PCR-ELISA Leuk Res. 23:625-30.
81. Suga S., Yoshikawa T., Asano Y., Nakashima T., Yazaki T., Fukuda M., Kojima S., Matsuyama T., Ono Y., and Oshima S. 1992. IgM neutralizing antibody responses to human herpesvirus-6 in patients with exanthem subitum or organ transplantation Microbiol Immunol. 36:495-506.
82. Ueda K., Kusuhara K., Hirose M., Okada K., Miyazaki C., Tokugawa K., Nakayama M., and Yamanishi K. 1989. Exanthem subitum and antibody to human herpesvirus-6 J Infect Dis. 159:750-2.
83. Asano Y., Nakashima T., Yoshikawa T., Suga S., and Yazaki T. 1991. Severity of human herpesvirus-6 viremia and clinical findings in infants with exanthem subitum J Pediatr. 118:891-5.
84. Maréchal V., Segondy M., and Nicolas J. C. Cytomégalovirus. Thérapeutique. In Elsevier (ed.), Les herpèsvirus humains. Clinique/Biologie/Diagnostic. Collection Option Bio.
85. Campadelli-Fiume G., Guerrini S., Liu X., and Foa-Tomasi L. 1993. Monoclonal antibodies to glycoprotein B differentiate human herpesvirus 6 into two clusters, variants A and B J Gen Virol. 74 ( Pt 10):2257-62.
86. Foa-Tomasi L., Avitabile E., and Campadelli-Fiume G. 1995. Selection of a monoclonal antibody specific for variant B human herpesvirus 6-infected mononuclear cells J Virol Methods. 51:289-96.
87. Cone R. W., Huang M. L., Ashley R., and Corey L. 1993. Human herpesvirus 6 DNA in peripheral blood cells and saliva from immunocompetent individuals J Clin Microbiol. 31:1262-7.
88. Secchiero P., Zella D., Crowley R. W., Gallo R. C., and Lusso P. 1995. Quantitative PCR for human herpesviruses 6 and 7 J Clin Microbiol. 33:2124-30.
89. Clark D. A., Ait-Khaled M., Wheeler A. C., Kidd I. M., McLaughlin J. E., Johnson M. A., Griffiths P. D., and Emery V. C. 1996. Quantification of human herpesvirus 6 in immunocompetent persons and post-mortem tissues from AIDS patients by PCR J Gen Virol. 77 ( Pt 9):2271-5.
90. Gautheret-Dejean A., Manichanh C., Thien-Ah-Koon F., Fillet A. M., Mangeney N., Vidaud M., Dhedin N., Vernant J. P., and Agut H. 2002. Development of a real-time polymerase chain reaction assay for the diagnosis of human herpesvirus-6 infection and application to bone marrow transplant patients J Virol Methods. 100:27-35.
91. Ingrand D. Les antiviraux, p. 211-224. In A. M. Collection Azay (ed.), Virologie médicale, vol. Chap 10. Presses Universitaires de Lyon, Lyon.
92. De Clerck E. 2003. Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrvirus infections. Expert Rev Anti-infect Ther. 1:21-43.
93. Shiraki K., Okuno T., Yamanishi K., and Takahashi M. 1989. Phosphonoacetic acid inhibits replication of human herpesvirus-6 Antiviral Res. 12:311-8.
94. Agut H., Collandre H., Aubin J. T., Guetard D., Favier V., Ingrand D., Montagnier L., and Huraux J. M. 1989. In vitro sensitivity of human herpesvirus-6 to antiviral drugs Res Virol. 140:219-28.
95. Yoshida M., Yamada M., Chatterjee S., Lakeman F., Nii S., and Whitley R. J. 1996. A method for detection of HHV-6 antigens and its use for evaluating antiviral drugs J Virol Methods. 58:137-43.
96. Yoshida M., Yamada M., Tsukazaki T., Chatterjee S., Lakeman F. D., Nii S., and Whitley R. J. 1998. Comparison of antiviral compounds against human herpesvirus 6 and 7 Antiviral Res. 40:73-84.
97. Qavi H. B., Wyde P. R., and Khan M. A. 2002. In vitro Inhibition of HHV-6 replication by sophocarpines Phytother Res. 16:154-6.
98. Manichanh C., Olivier-Aubron C., Lagarde J. P., Aubin J. T., Bossi P., Gautheret-Dejean A., Huraux J. M., and Agut H. 2001. Selection of the same mutation in the U69 protein kinase gene of human herpesvirus-6 after prolonged exposure to ganciclovir in vitro and in vivo J Gen Virol. 82:2767-76.
99. Mace M., Manichanh C., Bonnafous P., Precigout S., Boutolleau D., Gautheret-Dejean A., and Agut H. 2003. Real-time PCR as a versatile tool for investigating the susceptibility of human herpesvirus 6 to antiviral agents Antimicrob Agents Chemother. 47:3021-4.
100. Safronetz D., Petric M., Tellier R., Parvez B., and Tipples G. A. 2003. Mapping ganciclovir resistance in the human herpesvirus-6 U69 protein kinase J Med Virol. 71:434-9.
101. Inoue Y., Yasukawa M., and Fujita S. 1997. Induction of T-cell apoptosis by human herpesvirus 6 J Virol. 71:3751-9.
102. Yasukawa M., Inoue Y., Ohminami H., Terada K., and Fujita S. 1998. Apoptosis of CD4+ T lymphocytes in human herpesvirus-6 infection J Gen Virol. 79 ( Pt 1):143-7.
103. Ichimi R., Jin-no T., and Ito M. 1999. Induction of apoptosis in cord blood lymphocytes by HHV-6 J Med Virol. 58:63-8.
104. Parkin D. M., Muir C. S., Whelan S. L., Gao Y. T., Ferlay J., and Powell J. e. 1992. Cancer Incidence in Five Continents. Vol VI. n°120. World Health Organization, IARC Scientific Publications n°120. International Agency for Research on Cancer.
105. Rabkin C. S., Devesa S. S., Zahm S. H., and Gail M. H. 1993. Increasing incidence of non-Hodgkin's lymphoma Semin Hematol. 30:286-96.
106. Bouabdallah R., and Gastaut J. A. Lymphomes malins., p. 325-336. In S. G. (ed.), Hématologie clinique et biologique. Arnette.
107. Evans L. S., and Hancock B. W. 2003. Non-Hodgkin lymphoma Lancet. 362:139-46.
108. Harris N. L., Jaffe E. S., Diebold J., Flandrin G., Muller-Hermelink H. K., Vardiman J., Lister T. A., and Bloomfield C. D. 2000. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997 Histopathology. 36:69-86.
109. Lee M. S. 1993. Molecular aspects of chromosomal translocation t(14;18) Semin Hematol. 30:297-305.
110. Vilchez R. A., Madden C. R., Kozinetz C. A., Halvorson S. J., White Z. S., Jorgensen J. L., Finch C. J., and Butel J. S. 2002. Association between simian virus 40 and non-Hodgkin lymphoma Lancet. 359:817-23.
111. David H., Mendoza S., Konishi T., and Miller C. W. 2001. Simian virus 40 is present in human lymphomas and normal blood Cancer Lett. 162:57-64.
112. Shivapurkar N., Harada K., Reddy J., Scheuermann R. H., Xu Y., McKenna R. W., Milchgrub S., Kroft S. H., Feng Z., and Gazdar A. F. 2002. Presence of simian virus 40 DNA sequences in human lymphomas Lancet. 359:851-2.
113. Vilchez R. A., Kozinetz C. A., Arrington A. S., Madden C. R., and Butel J. S. 2003. Simian virus 40 in human cancers Am J Med. 114:675-84.
114. MacKenzie J., Wilson K. S., Perry J., Gallagher A., and Jarrett R. F. 2003. Association between simian virus 40 DNA and lymphoma in the United kingdom J Natl Cancer Inst. 95:1001-3.
115. Emberger J. M., Rousset T., and Taib J. La maladie de Hodgkin, conception actuelle. Laboratoire central d'hématologie, laboratoire d'anatomie pathologique. Hôpital St Eloi.
116. Hansmann M. L., Weiss L. M., Stein H., Harris N. L., and Jaffe E. S. 1999. Hodgkin's Disease. (Mauch PM., Armitage JO., Diehl V., Hoppe RT. Weiss LM., eds). Lippencott Williams & Wilkins, Philadelphia.:169-180.
117. Weiss L. M., Chan J. K. C., MacLennan K., and Warnke R. A. 1999. Hodgkin's Disease. (Mauch PM., Armitage JO., Diehl V., Hoppe RT. Weiss LM., eds). Lippencott Williams & Wilkins, Philadelphia.:101-120.
118. Kanzler H., Kuppers R., Hansmann M. L., and Rajewsky K. 1996. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells J Exp Med. 184:1495-505.
119. Hummel M., Ziemann K., Lammert H., Pileri S., Sabattini E., and Stein H. 1995. Hodgkin's disease with monoclonal and polyclonal populations of Reed-Sternberg cells N Engl J Med. 333:901-6.
120. Roers A., Montesinos-Rongen M., Hansmann M. L., Rajewsky K., and Kuppers R. 1998. Amplification of TCRbeta gene rearrangements from micromanipulated single cells: T cells rosetting around Hodgkin and Reed-Sternberg cells in Hodgkin's disease are polyclonal Eur J Immunol. 28:2424-31.
121. Harris N. L. 1999. Hodgkin's lymphomas: classification, diagnosis, and grading Semin Hematol. 36:220-32.
122. Anagnostopoulos I., Hansmann M. L., Franssila K., Harris M., Harris N. L., Jaffe E. S., Han J., van Krieken J. M., Poppema S., Marafioti T., Franklin J., Sextro M., Diehl V., and Stein H. 2000. European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes Blood. 96:1889-99.
123. Hodgkin T. 1832. On some morbid appearances of the absorbent glands and spleen. Med Chir Transactions. 17:68-114.
124. Seitz V., Hummel M., Anagnostopoulos I., and Stein H. 2001. Analysis of BCL-6 mutations in classic Hodgkin disease of the B- and T-cell type Blood. 97:2401-5.
125. Maggio E. M., Stekelenburg E., Van den Berg A., and Poppema S. 2001. TP53 gene mutations in Hodgkin lymphoma are infrequent and not associated with absence of Epstein-Barr virus Int J Cancer. 94:60-6.
126. Kupper M., Joos S., von Bonin F., Daus H., Pfreundschuh M., Lichter P., and Trumper L. 2001. MDM2 gene amplification and lack of p53 point mutations in Hodgkin and Reed-Sternberg cells: results from single-cell polymerase chain reaction and molecular cytogenetic studies Br J Haematol. 112:768-75.
127. Montesinos-Rongen M., Roers A., Kuppers R., Rajewsky K., and Hansmann M. L. 1999. Mutation of the p53 gene is not a typical feature of Hodgkin and Reed-Sternberg cells in Hodgkin's disease Blood. 94:1755-60.
128. Xerri L., Parc P., Bouabdallah R., Camerlo J., and Hassoun J. 1995. PCR-mismatch analysis of p53 gene mutation in Hodgkin's disease J Pathol. 175:189-94.
129. Muschen M., Re D., Brauninger A., Wolf J., Hansmann M. L., Diehl V., Kuppers R., and Rajewsky K. 2000. Somatic mutations of the CD95 gene in Hodgkin and Reed-Sternberg cells Cancer Res. 60:5640-3.
130. Trumper L., Pfreundschuh M., Jacobs G., von Bonin F., Loftin U., Moller P., and Daus H. 1996. N-ras genes are not mutated in Hodgkin and Reed-Sternberg cells: results from single cell polymerase chain-reaction examinations Leukemia. 10:727-30.
131. Shen H. M., Peters A., Baron B., Zhu X., and Storb U. 1998. Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes Science. 280:1750-2.
132. Lossos I. S., and Levy R. 2000. Mutation analysis of the 5' noncoding regulatory region of the BCL-6 gene in non-Hodgkin lymphoma: evidence for recurrent mutations and intraclonal heterogeneity Blood. 95:1400-5.
133. Wlodarska I., Nooyen P., Maes B., Martin-Subero J. I., Siebert R., Pauwels P., De Wolf-Peeters C., and Hagemeijer A. 2003. Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma Blood. 101:706-10.
134. Migliazza A., Martinotti S., Chen W., Fusco C., Ye B. H., Knowles D. M., Offit K., Chaganti R. S., and Dalla-Favera R. 1995. Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma Proc Natl Acad Sci U S A. 92:12520-4.
135. Baron B. W., Desai M., Baber L. J., Paras L., Zhang Q., Sadhu A., Duguay S., Nucifora G., McKeithan T. W., and Zeleznik-Le N. 1997. BCL6 can repress transcription from the human immunodeficiency virus type I promoter/enhancer region Genes Chromosomes Cancer. 19:14-21.
136. Ye B. H., Chaganti S., Chang C. C., Niu H., Corradini P., Chaganti R. S., and Dalla-Favera R. 1995. Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma Embo J. 14:6209-17.
137. Albagli-Curiel O. 2003. Ambivalent role of BCL6 in cell survival and transformation Oncogene. 22:507-16.
138. Kurosu T., Fukuda T., Miki T., and Miura O. 2003. BCL6 overexpression prevents increase in reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-cell lymphoma cells Oncogene. 22:4459-68.
139. Itoh N., Yonehara S., Ishii A., Yonehara M., Mizushima S., Sameshima M., Hase A., Seto Y., and Nagata S. 1991. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis Cell. 66:233-43.
140. Oehm A., Behrmann I., Falk W., Pawlita M., Maier G., Klas C., Li-Weber M., Richards S., Dhein J., Trauth B. C., and et al. 1992. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen J Biol Chem. 267:10709-15.
141. Falzetti D., Crescenzi B., Matteuci C., Falini B., Martelli M. F., Van Den Berghe H., and Mecucci C. 1999. Genomic instability and recurrent breakpoints are main cytogenetic findings in Hodgkin's disease Haematologica. 84:298-305.
142. Weber-Matthiesen K., Deerberg J., Poetsch M., Grote W., and Schlegelberger B. 1995. Numerical chromosome aberrations are present within the CD30+ Hodgkin and Reed-Sternberg cells in 100% of analyzed cases of Hodgkin's disease Blood. 86:1464-8.
143. Joos S., Kupper M., Ohl S., von Bonin F., Mechtersheimer G., Bentz M., Marynen P., Moller P., Pfreundschuh M., Trumper L., and Lichter P. 2000. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells Cancer Res. 60:549-52.
144. Ohshima K., Haraoka S., Fujiki T., Yoshioka S., Suzumiya J., Kanda M., and Kikuchi M. 1999. Expressions of cyclin E, A, and B1 in Hodgkin and Reed-Sternberg cells: not suppressed by cyclin-dependent kinase inhibitor p21 expression Pathol Int. 49:506-12.
145. Smolewski P., Niewiadomska H., Krykowski E., and Robak T. 1999. Expression of p21 and MDM-2 proteins on tumor cells in responding and non-responding patients with Hodgkin's disease Neoplasma. 46:212-8.
146. Kanavaros P., Stefanaki K., Vlachonikolis J., Eliopoulos G., Kakolyris S., Rontogianni D., Gorgoulis V., and Georgoulias V. 2000. Expression of p53, p21/waf1, bcl-2, bax, Rb and Ki67 proteins in Hodgkin's lymphomas Histol Histopathol. 15:445-53.
147. Rassidakis G. Z., Medeiros L. J., McDonnell T. J., Viviani S., Bonfante V., Nadali G., Vassilakopoulos T. P., Giardini R., Chilosi M., Kittas C., Gianni A. M., Bonadonna G., Pizzolo G., Pangalis G. A., Cabanillas F., and Sarris A. H. 2002. BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease: correlation with clinical outcome Clin Cancer Res. 8:488-93.
148. Re D., Benenson E., Wolf J., Diehl V., and Staratschek-Jox A. 2000. Lack of BCL10 mutations in Hodgkin's disease-derived cell lines Br J Haematol. 109:420-2.
149. Tzankov A., Zimpfer A., Lugli A., Krugmann J., Went P., Schraml P., Maurer R., Ascani S., Pileri S., Geley S., and Dirnhofer S. 2003. High-throughput tissue microarray analysis of G1-cyclin alterations in classical Hodgkin's lymphoma indicates overexpression of cyclin E1 J Pathol. 199:201-7.
150. Garcia M. J., Martinez-Delgado B., Cebrian A., Martinez A., Benitez J., and Rivas C. 2002. Different incidence and pattern of p15INK4b and p16INK4a promoter region hypermethylation in Hodgkin's and CD30-Positive non-Hodgkin's lymphomas Am J Pathol. 161:1007-13.
151. Doussis-Anagnostopoulou I. A., Talks K. L., Turley H., Debnam P., Tan D. C., Mariatos G., Gorgoulis V., Kittas C., and Gatter K. C. 2002. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease J Pathol. 197:677-83.
152. Garcia J. F., Camacho F. I., Morente M., Fraga M., Montalban C., Alvaro T., Bellas C., Castano A., Diez A., Flores T., Martin C., Martinez M. A., Mazorra F., Menarguez J., Mestre M. J., Mollejo M., Saez A. I., Sanchez L., and Piris M. A. 2003. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays Blood. 101:681-9.
153. Mathas S., Hinz M., Anagnostopoulos I., Krappmann D., Lietz A., Jundt F., Bommert K., Mechta-Grigoriou F., Stein H., Dorken B., and Scheidereit C. 2002. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B Embo J. 21:4104-13.
154. Garcia J. F., Villuendas R., Algara P., Saez A. I., Sanchez-Verde L., Martinez-Montero J. C., Martinez P., and Piris M. A. 1999. Loss of p16 protein expression associated with methylation of the p16INK4A gene is a frequent finding in Hodgkin's disease Lab Invest. 79:1453-9.
155. Guenova M., Rassidakis G. Z., Gorgoulis V. G., Angelopoulou M. K., Siakantaris M. R., Kanavaros P., Pangalis G. A., and Kittas C. 1999. p16INK4A is regularly expressed in Hodgkin's disease: comparison with retinoblastoma, p53 and MDM2 protein status, and the presence of Epstein-Barr virus Mod Pathol. 12:1062-71.
156. Serrano M., Hannon G. J., and Beach D. 1993. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 Nature. 366:704-7.
157. Okamoto A., Demetrick D. J., Spillare E. A., Hagiwara K., Hussain S. P., Bennett W. P., Forrester K., Gerwin B., Greenblatt M. S., Serrano M., and et al. 1994. p16INK4 mutations and altered expression in human tumors and cell lines Cold Spring Harb Symp Quant Biol. 59:49-57.
158. Okamoto A., Demetrick D. J., Spillare E. A., Hagiwara K., Hussain S. P., Bennett W. P., Forrester K., Gerwin B., Serrano M., Beach D. H., and et al. 1994. Mutations and altered expression of p16INK4 in human cancer Proc Natl Acad Sci U S A. 91:11045-9.
159. Boise L. H., Gonzalez-Garcia M., Postema C. E., Ding L., Lindsten T., Turka L. A., Mao X., Nunez G., and Thompson C. B. 1993. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death Cell. 74:597-608.
160. Kube D., Holtick U., Vockerodt M., Ahmadi T., Haier B., Behrmann I., Heinrich P. C., Diehl V., and Tesch H. 2001. STAT3 is constitutively activated in Hodgkin cell lines Blood. 98:762-70.
161. Skinnider B. F., Elia A. J., Gascoyne R. D., Patterson B., Trumper L., Kapp U., and Mak T. W. 2002. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma Blood. 99:618-26.
162. Heim M. H., Kerr I. M., Stark G. R., and Darnell J. E., Jr. 1995. Contribution of STAT SH2 groups to specific interferon signaling by the Jak-STAT pathway Science. 267:1347-9.
163. Gupta S., Yan H., Wong L. H., Ralph S., Krolewski J., and Schindler C. 1996. The SH2 domains of Stat1 and Stat2 mediate multiple interactions in the transduction of IFN-alpha signals Embo J. 15:1075-84.
164. Scholz A., Heinze S., Detjen K. M., Peters M., Welzel M., Hauff P., Schirner M., Wiedenmann B., and Rosewicz S. 2003. Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer Gastroenterology. 125:891-905.
165. Turkson J., Bowman T., Garcia R., Caldenhoven E., De Groot R. P., and Jove R. 1998. Stat3 activation by Src induces specific gene regulation and is required for cell transformation Mol Cell Biol. 18:2545-52.
166. Bargou R. C., Leng C., Krappmann D., Emmerich F., Mapara M. Y., Bommert K., Royer H. D., Scheidereit C., and Dorken B. 1996. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells Blood. 87:4340-7.
167. Bargou R. C., Emmerich F., Krappmann D., Bommert K., Mapara M. Y., Arnold W., Royer H. D., Grinstein E., Greiner A., Scheidereit C., and Dorken B. 1997. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells J Clin Invest. 100:2961-9.
168. Krappmann D., Emmerich F., Kordes U., Scharschmidt E., Dorken B., and Scheidereit C. 1999. Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells Oncogene. 18:943-53.
169. Cabannes E., Khan G., Aillet F., Jarrett R. F., and Hay R. T. 1999. Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha Oncogene. 18:3063-70.
170. Emmerich F., Meiser M., Hummel M., Demel G., Foss H. D., Jundt F., Mathas S., Krappmann D., Scheidereit C., Stein H., and Dorken B. 1999. Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells Blood. 94:3129-34.
171. Hinz M., Lemke P., Anagnostopoulos I., Hacker C., Krappmann D., Mathas S., Dorken B., Zenke M., Stein H., and Scheidereit C. 2002. Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity J Exp Med. 196:605-17.
172. Re D., Hofmann A., Wolf J., Diehl V., and Staratschek-Jox A. 2000. Cultivated H-RS cells are resistant to CD95L-mediated apoptosis despite expression of wild-type CD95 Exp Hematol. 28:31-5.
173. Klein S., Jucker M., Diehl V., and Tesch H. 1992. Production of multiple cytokines by Hodgkin's disease derived cell lines Hematol Oncol. 10:319-29.
174. Blay J. Y., Farcet J. P., Lavaud A., Radoux D., and Chouaib S. 1994. Serum concentrations of cytokines in patients with Hodgkin's disease Eur J Cancer. 30A:321-4.
175. Krueger G. R., Guenther A., Knuefermann R., Kluppelberg U., Luka J., Pearson G. R., Ablashi D. V., Juecker M., and Tesch H. 1994. Human herpesvirus-6 (HHV-6) in Hodgkin's disease: cellular expression of viral antigens as compared to oncogenes met and fes, tumor suppressor gene product p53, and interleukins 2 and 6 In Vivo. 8:501-16.
176. Kurzrock R. 1997. Cytokine deregulation in hematological malignancies: clinical and biological implications Clin Cancer Res. 3:2581-4.
177. Foss H. D., Herbst H., Oelmann E., Samol J., Grebe M., Blankenstein T., Matthes J., Qin Z. H., Falini B., Pileri S., and et al. 1993. Lymphotoxin, tumour necrosis factor and interleukin-6 gene transcripts are present in Hodgkin and Reed-Sternberg cells of most Hodgkin's disease cases Br J Haematol. 84:627-35.
178. Tesch H., Feller A. C., Jucker M., Klein S., Merz H., and Diehl V. 1992. Activation of cytokines in Hodgkin's disease Ann Oncol. 3 Suppl 4:13-6.
179. Tesch H., Jucker M., Klein S., Abts H., Gunther A., Krueger G. R., and Diehl V. 1992. Hodgkin and Reed-Sternberg cells express interleukin 6 and interleukin 6 receptors Leuk Lymphoma. 7:297-303.
180. Gause A., Scholz R., Klein S., Jung W., Diehl V., Tesch H., Hasenclever D., and Pfreundschuh M. 1991. Increased levels of circulating interleukin-6 in patients with Hodgkin's disease Hematol Oncol. 9:307-13.
181. Reynolds G. M., Billingham L. J., Gray L. J., Flavell J. R., Najafipour S., Crocker J., Nelson P., Young L. S., and Murray P. G. 2002. Interleukin 6 expression by Hodgkin/Reed-Sternberg cells is associated with the presence of 'B' symptoms and failure to achieve complete remission in patients with advanced Hodgkin's disease Br J Haematol. 118:195-201.
182. Aldinucci D., Poletto D., Gloghini A., Nanni P., Degan M., Perin T., Ceolin P., Rossi F. M., Gattei V., Carbone A., and Pinto A. 2002. Expression of functional interleukin-3 receptors on Hodgkin and Reed-Sternberg cells Am J Pathol. 160:585-96.
183. Skinnider B. F., Elia A. J., Gascoyne R. D., Trumper L. H., von Bonin F., Kapp U., Patterson B., Snow B. E., and Mak T. W. 2001. Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma Blood. 97:250-5.
184. Kapp U., Yeh W. C., Patterson B., Elia A. J., Kagi D., Ho A., Hessel A., Tipsword M., Williams A., Mirtsos C., Itie A., Moyle M., and Mak T. W. 1999. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells J Exp Med. 189:1939-46.
185. Weiss L. M., Chen Y. Y., Liu X. F., and Shibata D. 1991. Epstein-Barr virus and Hodgkin's disease. A correlative in situ hybridization and polymerase chain reaction study Am J Pathol. 139:1259-65.
186. Mitarnun W., Pradutkanchana J., Takao S., Saechan V., Suwiwat S., and Ishida T. 2002. Epstein-barr virus-associated non-Hodgkin's lymphoma of B-cell origin, Hodgkin's disease, acute leukemia, and systemic lupus erythematosus: a serologic and molecular analysis J Med Assoc Thai. 85:552-9.
187. Herndier B. G., Sanchez H. C., Chang K. L., Chen Y. Y., and Weiss L. M. 1993. High prevalence of Epstein-Barr virus in the Reed-Sternberg cells of HIV-associated Hodgkin's disease Am J Pathol. 142:1073-9.
188. Cordova Perez F. J., Gonzalez-Keelan C. I., and Velez R. 2003. Epstein-Barr virus in biopsies from patients with Hodgkin and non-Hodgkin lymphoma at the University of Puerto Rico immunohistochemistry laboratory P R Health Sci J. 22:125-9.
189. Shibata D., Hansmann M. L., Weiss L. M., and Nathwani B. N. 1991. Epstein-Barr virus infections and Hodgkin's disease: a study of fixed tissues using the polymerase chain reaction Hum Pathol. 22:1262-7.
190. Flavell K. J., Billingham L. J., Biddulph J. P., Gray L., Flavell J. R., Constandinou C. M., Young L. S., and Murray P. G. 2003. The effect of Epstein-Barr virus status on outcome in age- and sex-defined subgroups of patients with advanced Hodgkin's disease Ann Oncol. 14:282-90.
191. Boyle M. J., Vasak E., Tschuchnigg M., Turner J. J., Sculley T., Penny R., Cooper D. A., Tindall B., and Sewell W. A. 1993. Subtypes of Epstein-Barr virus (EBV) in Hodgkin's disease: association between B-type EBV and immunocompromise Blood. 81:468-74.
192. Gledhill S., Krajewski A. S., and Jarrett R. F. 1991. Demonstration of Epstein-Barr viral DNA in formalin-fixed, paraffin-embedded samples of Hodgkin's disease J Pathol. 163:149-51.
193. Kandil A., Bazarbashi S., and Mourad W. A. 2001. The correlation of Epstein-Barr virus expression and lymphocyte subsets with the clinical presentation of nodular sclerosing Hodgkin disease Cancer. 91:1957-63.
194. Staal S. P., Ambinder R., Beschorner W. E., Hayward G. S., and Mann R. 1989. A survey of Epstein-Barr virus DNA in lymphoid tissue. Frequent detection in Hodgkin's disease Am J Clin Pathol. 91:1-5.
195. Grasser F. A., Murray P. G., Kremmer E., Klein K., Remberger K., Feiden W., Reynolds G., Niedobitek G., Young L. S., and Mueller-Lantzsch N. 1994. Monoclonal antibodies directed against the Epstein-Barr virus-encoded nuclear antigen 1 (EBNA1): immunohistologic detection of EBNA1 in the malignant cells of Hodgkin's disease Blood. 84:3792-8.
196. Elgui de Oliveira D., Bacchi M. M., Abreu E. S., Niero-Melo L., and Bacchi C. E. 2002. Hodgkin disease in adult and juvenile groups from two different geographic regions in Brazil: characterization of clinicopathologic aspects and relationship with Epstein-Barr virus infection Am J Clin Pathol. 118:25-30.
197. Hummel M., Anagnostopoulos I., Dallenbach F., Korbjuhn P., Dimmler C., and Stein H. 1992. EBV infection patterns in Hodgkin's disease and normal lymphoid tissue: expression and cellular localization of EBV gene products Br J Haematol. 82:689-94.
198. Gulley M. L., Eagan P. A., Quintanilla-Martinez L., Picado A. L., Smir B. N., Childs C., Dunn C. D., Craig F. E., Williams J. W., Jr., and Banks P. M. 1994. Epstein-Barr virus DNA is abundant and monoclonal in the Reed-Sternberg cells of Hodgkin's disease: association with mixed cellularity subtype and Hispanic American ethnicity Blood. 83:1595-602.
199. Jarrett R. F., Gallagher A., Jones D. B., Alexander F. E., Krajewski A. S., Kelsey A., Adams J., Angus B., Gledhill S., Wright D. H., and et al. 1991. Detection of Epstein-Barr virus genomes in Hodgkin's disease: relation to age J Clin Pathol. 44:844-8.
200. Peh S. C., Kim L. H., and Poppema S. 2002. Frequent presence of subtype A virus in Epstein-Barr virus-associated malignancies Pathology. 34:446-50.
201. De Re V., De Vita S., Dolcetti R., and Boiocchi M. 1993. Association between B-type Epstein-Barr virus and Hodgkin's disease in immunocompromised patients Blood. 82:328-30.
202. Stachura T., and Malinowski E. 2003. Primary pulmonary Hodgkin's lymphoma with Epstein-Barr and cytomegaly virus infections. A case report and differential diagnosis Pol J Pathol. 54:79-83.
203. Tirelli U., Vaccher E., Rezza G., Barbui T., Bernasconi C., Cajozzo A., Cargnel A., de Lalla F., Dessalvi P., Fassio P. G., and et al. 1989. Hodgkin's disease in association with acquired immunodeficiency syndrome (AIDS). A report on 36 patients. Gruppo Italiano Cooperativo AIDS and Tumori Acta Oncol. 28:637-9.
204. Alfonso P. G., Sanudo E. F., Carretero J. M., Galindo R. C., Altozano J. G., Gomez L. P., and Manga G. P. 1988. Hodgkin's disease in HIV-infected patients Biomed Pharmacother. 42:321-5.
205. Gold J. E., Altarac D., Ree H. J., Khan A., Sordillo P. P., and Zalusky R. 1991. HIV-associated Hodgkin disease: a clinical study of 18 cases and review of the literature Am J Hematol. 36:93-9.
206. Andrieu J. M., Roithmann S., Tourani J. M., Levy R., Desablens B., le Maignan C., Gastaut J. A., Brice P., Raphael M., and Taillan B. 1993. Hodgkin's disease during HIV1 infection: the French registry experience. French Registry of HIV-associated Tumors Ann Oncol. 4:635-41.
207. Grulich A. E., Wan X., Law M. G., Coates M., and Kaldor J. M. 1999. Risk of cancer in people with AIDS Aids. 13:839-43.
208. Frisch M., Biggar R. J., Engels E. A., and Goedert J. J. 2001. Association of cancer with AIDS-related immunosuppression in adults Jama. 285:1736-45.
209. Ames E. D., Conjalka M. S., Goldberg A. F., Hirschman R., Jain S., Distenfeld A., and Metroka C. E. 1991. Hodgkin's disease and AIDS. Twenty-three new cases and a review of the literature Hematol Oncol Clin North Am. 5:343-56.
210. Diwan A. H., Umbreit J., and Nelson B. P. 2002. Long-term survival of a patient with human immunodeficiency virus infection and Hodgkin's lymphoma South Med J. 95:943-4.
211. Gerard L., Galicier L., Boulanger E., Quint L., Lebrette M. G., Mortier E., Meignin V., and Oksenhendler E. 2003. Improved survival in HIV-related Hodgkin's lymphoma since the introduction of highly active antiretroviral therapy Aids. 17:81-7.
212. Lederman M. M., and Valdez H. 2000. Immune restoration with antiretroviral therapies: implications for clinical management Jama. 284:223-8.
213. Schmidt C. A., Oettle H., Peng R., Binder T., Wilborn F., Huhn D., Siegert W., and Herbst H. 2000. Presence of human beta- and gamma-herpes virus DNA in Hodgkin's disease Leuk Res. 24:865-70.
214. Berneman Z. N., Torelli G., Luppi M., and Jarrett R. F. 1998. Absence of a directly causative role for human herpesvirus 7 in human lymphoma and a review of human herpesvirus 6 in human malignancy Ann Hematol. 77:275-8.
215. Secchiero P., Bonino L. D., Lusso P., Abele M. C., Reato G., Kerim S., Palestro G., Zauli G., and Valente G. 1998. Human herpesvirus type 7 in Hodgkin's disease Br J Haematol. 101:492-9.
216. Benharroch D., Shemer-Avni Y., Levy A., Myint Y. Y., Ariad S., Rager B., Sacks M., and Gopas J. 2003. New candidate virus in association with Hodgkin's disease Leuk Lymphoma. 44:605-10.
217. Mori S., Maruyama H., Ito I., Tokuhira M., Koide J., Takeuchi T., Itoyama S., Masunaga A., Fukushima M., Suzuki H., and Abe T. 1998. Diagnosis of measles viral pneumonia in a patient with Hodgkin's disease by reverse transcription-polymerase chain reaction of serum Int J Hematol. 68:327-31.
218. Biberfeld P., Petren A. L., Eklund A., Lindemalm C., Barkhem T., Ekman M., Ablashi D., and Salahuddin Z. 1988. Human herpesvirus-6 (HHV-6, HBLV) in sarcoidosis and lymphoproliferative disorders J Virol Methods. 21:49-59.
219. Shanavas K. R., Kala V., Vasudevan D. M., Vijayakumar T., and Yadav M. 1992. Anti-HHV-6 antibodies in normal population and in cancer patients in India J Exp Pathol. 6:95-105.
220. Rojo J., Ferrer Argote V. E., Klueppelberg U., Krueger G. R., Eidt E., Ablashi D. V., Luka J., and Tesch H. 1994. Semi-quantitative in situ hybridization and immunohistology for antigen expression of human herpesvirus-6 in various lymphoproliferative diseases In Vivo. 8:517-26.
221. Borisch B., Ellinger K., Neipel F., Fleckenstein B., Kirchner T., Ott M. M., and Muller-Hermelink H. K. 1991. Lymphadenitis and lymphoproliferative lesions associated with the human herpes virus-6 (HHV-6) Virchows Arch B Cell Pathol Incl Mol Pathol. 61:179-87.
222. Valente G., Secchiero P., Lusso P., Abete M. C., Jemma C., Reato G., Kerim S., Gallo R. C., and Palestro G. 1996. Human herpesvirus 6 and Epstein-Barr virus in Hodgkin's disease: a controlled study by polymerase chain reaction and in situ hybridization Am J Pathol. 149:1501-10.
223. Buchbinder A., Josephs S. F., Ablashi D., Salahuddin S. Z., Klotman M. E., Manak M., Krueger G. R., Wong-Staal F., and Gallo R. C. 1988. Polymerase chain reaction amplification and in situ hybridization for the detection of human B-lymphotropic virus J Virol Methods. 21:191-7.
224. Maeda A., Sata T., Enzan H., Tanaka K., Wakiguchi H., Kurashige T., Yamanishi K., and Kurata T. 1993. The evidence of human herpesvirus 6 infection in the lymph nodes of Hodgkin's disease Virchows Arch A Pathol Anat Histopathol. 423:71-5.
225. Flamand L., Stefanescu I., Ablashi D. V., and Menezes J. 1993. Activation of the Epstein-Barr virus replicative cycle by human herpesvirus 6 J Virol. 67:6768-77.
226. Cuomo L., Trivedi P., de Grazia U., Calogero A., D'Onofrio M., Yang W., Frati L., Faggioni A., Rymo L., and Ragona G. 1998. Upregulation of Epstein-Barr virus-encoded latent membrane protein by human herpesvirus 6 superinfection of EBV-carrying Burkitt lymphoma cells J Med Virol. 55:219-26.
227. Flamand L., and Menezes J. 1996. Cyclic AMP-responsive element-dependent activation of Epstein-Barr virus zebra promoter by human herpesvirus 6 J Virol. 70:1784-91.
228. Razzaque A. 1990. Oncogenic potential of human herpesvirus-6 DNA Oncogene. 5:1365-70.
229. Razzaque A., Williams O., Wang J., and Rhim J. S. 1993. Neoplastic transformation of immortalized human epidermal keratinocytes by two HHV-6 DNA clones Virology. 195:113-20.
230. Thompson J., Choudhury S., Kashanchi F., Doniger J., Berneman Z., Frenkel N., and Rosenthal L. J. 1994. A transforming fragment within the direct repeat region of human herpesvirus type 6 that transactivates HIV-1 Oncogene. 9:1167-75.
231. Bagchi S., Weinmann R., and Raychaudhuri P. 1991. The retinoblastoma protein copurifies with E2F-I, an E1A-regulated inhibitor of the transcription factor E2F Cell. 65:1063-72.
232. Muller H., Bracken A. P., Vernell R., Moroni M. C., Christians F., Grassilli E., Prosperini E., Vigo E., Oliner J. D., and Helin K. 2001. E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis Genes Dev. 15:267-85.
233. Lane D. P. 1992. Cancer. p53, guardian of the genome Nature. 358:15-6.
234. Lamb P., and Crawford L. 1986. Characterization of the human p53 gene Mol Cell Biol. 6:1379-85.
235. Isobe M., Emanuel B. S., Givol D., Oren M., and Croce C. M. 1986. Localization of gene for human p53 tumour antigen to band 17p13 Nature. 320:84-5.
236. Yang A., Kaghad M., Wang Y., Gillett E., Fleming M. D., Dotsch V., Andrews N. C., Caput D., and McKeon F. 1998. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities Mol Cell. 2:305-16.
237. Schmale H., and Bamberger C. 1997. A novel protein with strong homology to the tumor suppressor p53 Oncogene. 15:1363-7.
238. Kaghad M., Bonnet H., Yang A., Creancier L., Biscan J. C., Valent A., Minty A., Chalon P., Lelias J. M., Dumont X., Ferrara P., McKeon F., and Caput D. 1997. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers Cell. 90:809-19.
239. Jayaraman L., and Prives C. 1999. Covalent and noncovalent modifiers of the p53 protein Cell Mol Life Sci. 55:76-87.
240. Chene P. 2001. The role of tetramerization in p53 function Oncogene. 20:2611-7.
241. Gulbis J. M., Kelman Z., Hurwitz J., O'Donnell M., and Kuriyan J. 1996. Structure of the C-terminal region of p21(WAF1/CIP1) complexed with human PCNA Cell. 87:297-306.
242. Azzam E. I., de Toledo S. M., Pykett M. J., Nagasawa H., and Little J. B. 1997. CDC2 is down-regulated by ionizing radiation in a p53-dependent manner Cell Growth Differ. 8:1161-9.
243. Pines J., and Hunter T. 1989. Isolation of a human cyclin cDNA: evidence for cyclin mRNA and protein regulation in the cell cycle and for interaction with p34cdc2 Cell. 58:833-46.
244. Taylor W. R., and Stark G. R. 2001. Regulation of the G2/M transition by p53 Oncogene. 20:1803-15.
245. Zhan Q., Antinore M. J., Wang X. W., Carrier F., Smith M. L., Harris C. C., and Fornace A. J., Jr. 1999. Association with Cdc2 and inhibition of Cdc2/Cyclin B1 kinase activity by the p53-regulated protein Gadd45 Oncogene. 18:2892-900.
246. Bunz F., Dutriaux A., Lengauer C., Waldman T., Zhou S., Brown J. P., Sedivy J. M., Kinzler K. W., and Vogelstein B. 1998. Requirement for p53 and p21 to sustain G2 arrest after DNA damage Science. 282:1497-501.
247. Chan T. A., Hermeking H., Lengauer C., Kinzler K. W., and Vogelstein B. 1999. 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage Nature. 401:616-20.
248. Ababneh M., Gotz C., and Montenarh M. 2001. Downregulation of the cdc2/cyclin B protein kinase activity by binding of p53 to p34(cdc2) Biochem Biophys Res Commun. 283:507-12.
249. Yun J., Chae H. D., Choy H. E., Chung J., Yoo H. S., Han M. H., and Shin D. Y. 1999. p53 negatively regulates cdc2 transcription via the CCAAT-binding NF-Y transcription factor J Biol Chem. 274:29677-82.
250. Kazantsev A., and Sancar A. 1995. Does the p53 up-regulated Gadd45 protein have a role in excision repair? Science. 270:1003-4; author reply 1005-6.
251. Kearsey J. M., Shivji M. K., Hall P. A., and Wood R. D. 1995. Does the p53 up-regulated Gadd45 protein have a role in excision repair? Science. 270:1004-5; author reply 1005-6.
252. Smith M. L., Chen I. T., Zhan Q., Bae I., Chen C. Y., Gilmer T. M., Kastan M. B., O'Connor P. M., and Fornace A. J., Jr. 1994. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen Science. 266:1376-80.
253. Carrier F., Georgel P. T., Pourquier P., Blake M., Kontny H. U., Antinore M. J., Gariboldi M., Myers T. G., Weinstein J. N., Pommier Y., and Fornace A. J., Jr. 1999. Gadd45, a p53-responsive stress protein, modifies DNA accessibility on damaged chromatin Mol Cell Biol. 19:1673-85.
254. Wang Q., Zhu Q., Wani M. A., Wani G., Chen J., and Wani A. A. 2003. Tumor suppressor p53 dependent recruitment of nucleotide excision repair factors XPC and TFIIH to DNA damage DNA Repair (Amst). 2:483-99.
255. Mummenbrauer T., Janus F., Muller B., Wiesmuller L., Deppert W., and Grosse F. 1996. p53 Protein exhibits 3'-to-5' exonuclease activity Cell. 85:1089-99.
256. Lilling G., Elena N., Sidi Y., and Bakhanashvili M. 2003. p53-associated 3'-->5' exonuclease activity in nuclear and cytoplasmic compartments of cells Oncogene. 22:233-45.
257. Miyashita T., and Reed J. C. 1995. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene Cell. 80:293-9.
258. Buckbinder L., Talbott R., Velasco-Miguel S., Takenaka I., Faha B., Seizinger B. R., and Kley N. 1995. Induction of the growth inhibitor IGF-binding protein 3 by p53 Nature. 377:646-9.
259. Owen-Schaub L. B., Zhang W., Cusack J. C., Angelo L. S., Santee S. M., Fujiwara T., Roth J. A., Deisseroth A. B., Zhang W. W., Kruzel E., and et al. 1995. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression Mol Cell Biol. 15:3032-40.
260. Gupta S., Radha V., Furukawa Y., and Swarup G. 2001. Direct transcriptional activation of human caspase-1 by tumor suppressor p53 J Biol Chem. 276:10585-8.
261. MacLachlan T. K., and El-Deiry W. S. 2002. Apoptotic threshold is lowered by p53 transactivation of caspase-6 Proc Natl Acad Sci U S A. 99:9492-7.
262. Reed J. C. 1994. Bcl-2 and the regulation of programmed cell death J Cell Biol. 124:1-6.
263. Haupt Y., Maya R., Kazaz A., and Oren M. 1997. Mdm2 promotes the rapid degradation of p53 Nature. 387:296-9.
264. Lin J., Chen J., Elenbaas B., and Levine A. J. 1994. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein Genes Dev. 8:1235-46.
265. Thut C. J., Chen J. L., Klemm R., and Tjian R. 1995. p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60 Science. 267:100-4.
266. Kobet E., Zeng X., Zhu Y., Keller D., and Lu H. 2000. MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins Proc Natl Acad Sci U S A. 97:12547-52.
267. Kubbutat M. H., Jones S. N., and Vousden K. H. 1997. Regulation of p53 stability by Mdm2 Nature. 387:299-303.
268. Wu X., Bayle J. H., Olson D., and Levine A. J. 1993. The p53-mdm-2 autoregulatory feedback loop Genes Dev. 7:1126-32.
269. Yamaguchi A., Tamatani M., Matsuzaki H., Namikawa K., Kiyama H., Vitek M. P., Mitsuda N., and Tohyama M. 2001. Akt activation protects hippocampal neurons from apoptosis by inhibiting transcriptional activity of p53 J Biol Chem. 276:5256-64.
270. Leng R. P., Lin Y., Ma W., Wu H., Lemmers B., Chung S., Parant J. M., Lozano G., Hakem R., and Benchimol S. 2003. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation Cell. 112:779-91.
271. Vaziri H., Dessain S. K., Ng Eaton E., Imai S. I., Frye R. A., Pandita T. K., Guarente L., and Weinberg R. A. 2001. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase Cell. 107:149-59.
272. Frade R., Balbo M., and Barel M. 2002. RB18A regulates p53-dependent apoptosis Oncogene. 21:861-6.
273. Hollstein M., Sidransky D., Vogelstein B., and Harris C. C. 1991. p53 mutations in human cancers Science. 253:49-53.
274. Werness B. A., Levine A. J., and Howley P. M. 1990. Association of human papillomavirus types 16 and 18 E6 proteins with p53 Science. 248:76-9.
275. Lane D. P., and Crawford L. V. 1979. T antigen is bound to a host protein in SV40-transformed cells Nature. 278:261-3.
276. Sarnow P., Ho Y. S., Williams J., and Levine A. J. 1982. Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells Cell. 28:387-94.
277. Feitelson M. A., Zhu M., Duan L. X., and London W. T. 1993. Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma Oncogene. 8:1109-17.
278. Speir E., Huang E. S., Modali R., Leon M. B., Shawl F., Finkel T., and Epstein S. E. 1995. Interaction of human cytomegalovirus with p53: possible role in coronary restenosis Scand J Infect Dis Suppl. 99:78-81.
279. Zhang Q., Gutsch D., and Kenney S. 1994. Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency Mol Cell Biol. 14:1929-38.
280. Yoshimura S., Morishita R., Hayashi K., Yamamoto K., Nakagami H., Kaneda Y., Sakai N., and Ogihara T. 2001. Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element 'decoy' of nuclear factor-kappaB binding site as a novel molecular strategy Gene Ther. 8:1635-42.
281. Schmitz M. L., and Baeuerle P. A. 1991. The p65 subunit is responsible for the strong transcription activating potential of NF-kappa B Embo J. 10:3805-17.
282. Baeuerle P. A., and Baltimore D. 1989. A 65-kappaD subunit of active NF-kappaB is required for inhibition of NF-kappaB by I kappaB Genes Dev. 3:1689-98.
283. May M. J., and Ghosh S. 1998. Signal transduction through NF-kappa B Immunol Today. 19:80-8.
284. Chen Z. J., Parent L., and Maniatis T. 1996. Site-specific phosphorylation of IkappaBalpha by a novel ubiquitination-dependent protein kinase activity Cell. 84:853-62.
285. Traenckner E. B., Pahl H. L., Henkel T., Schmidt K. N., Wilk S., and Baeuerle P. A. 1995. Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli Embo J. 14:2876-83.
286. Brockman J. A., Scherer D. C., McKinsey T. A., Hall S. M., Qi X., Lee W. Y., and Ballard D. W. 1995. Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappa B activation Mol Cell Biol. 15:2809-18.
287. Sen R., and Baltimore D. 1986. Multiple nuclear factors interact with the immunoglobulin enhancer sequences Cell. 46:705-16.
288. Tensen C. P., Flier J., Rampersad S. S., Sampat-Sardjoepersad S., Scheper R. J., Boorsma D. M., and Willemze R. 1999. Genomic organization, sequence and transcriptional regulation of the human CXCL 11(1) gene Biochim Biophys Acta. 1446:167-72.
289. Hein H., Schluter C., Kulke R., Christophers E., Schroder J. M., and Bartels J. 1997. Genomic organization, sequence, and transcriptional regulation of the human eotaxin gene Biochem Biophys Res Commun. 237:537-42.
290. Mori A., Suko M., Kaminuma O., Nishizaki Y., Nagahori T., Mikami T., Ohmura T., Hosino A., Asakura Y., and Okudaira H. 1996. Enhanced production and gene expression of IL-5 in bronchial asthma. Possible management of atopic diseases with IL-5 specific gene transcription inhibitor Adv Exp Med Biol. 409:439-50.
291. Hiscott J., Marois J., Garoufalis J., D'Addario M., Roulston A., Kwan I., Pepin N., Lacoste J., Nguyen H., Bensi G., and et al. 1993. Characterization of a functional NF-kappa B site in the human interleukin 1 beta promoter: evidence for a positive autoregulatory loop Mol Cell Biol. 13:6231-40.
292. Lai J. H., Horvath G., Subleski J., Bruder J., Ghosh P., and Tan T. H. 1995. RelA is a potent transcriptional activator of the CD28 response element within the interleukin 2 promoter Mol Cell Biol. 15:4260-71.
293. Libermann T. A., and Baltimore D. 1990. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor Mol Cell Biol. 10:2327-34.
294. Shakhov A. N., Collart M. A., Vassalli P., Nedospasov S. A., and Jongeneel C. V. 1990. Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages J Exp Med. 171:35-47.
295. Catz S. D., and Johnson J. L. 2001. Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer Oncogene. 20:7342-51.
296. Chen F., Demers L. M., Vallyathan V., Lu Y., Castranova V., and Shi X. 1999. Involvement of 5'-flanking kappaB-like sites within bcl-x gene in silica-induced Bcl-x expression J Biol Chem. 274:35591-5.
297. Wu H., and Lozano G. 1994. NF-kappa B activation of p53. A potential mechanism for suppressing cell growth in response to stress J Biol Chem. 269:20067-74.
298. Guttridge D. C., Albanese C., Reuther J. Y., Pestell R. G., and Baldwin A. S., Jr. 1999. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1 Mol Cell Biol. 19:5785-99.
299. Hinz M., Krappmann D., Eichten A., Heder A., Scheidereit C., and Strauss M. 1999. NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition Mol Cell Biol. 19:2690-8.
300. Sovak M. A., Bellas R. E., Kim D. W., Zanieski G. J., Rogers A. E., Traish A. M., and Sonenshein G. E. 1997. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer J Clin Invest. 100:2952-60.
301. Wang W., Abbruzzese J. L., Evans D. B., Larry L., Cleary K. R., and Chiao P. J. 1999. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells Clin Cancer Res. 5:119-27.
302. Giri D. K., and Aggarwal B. B. 1998. Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates J Biol Chem. 273:14008-14.
303. Jungnickel B., Staratschek-Jox A., Brauninger A., Spieker T., Wolf J., Diehl V., Hansmann M. L., Rajewsky K., and Kuppers R. 2000. Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma J Exp Med. 191:395-402.
304. Jiang H. Y., Petrovas C., and Sonenshein G. E. 2002. RelB-p50 NF-kappa B complexes are selectively induced by cytomegalovirus immediate-early protein 1: differential regulation of Bcl-x(L) promoter activity by NF-kappa B family members J Virol. 76:5737-47.
305. Yurochko A. D., Kowalik T. F., Huong S. M., and Huang E. S. 1995. Human cytomegalovirus upregulates NF-kappa B activity by transactivating the NF-kappa B p105/p50 and p65 promoters J Virol. 69:5391-400.
306. Yurochko A. D., Mayo M. W., Poma E. E., Baldwin A. S., Jr., and Huang E. S. 1997. Induction of the transcription factor Sp1 during human cytomegalovirus infection mediates upregulation of the p65 and p105/p50 NF-kappaB promoters J Virol. 71:4638-48.
307. Chien M. L., and Hammarskjold M. L. 2000. Epstein-barr virus latent membrane protein (LMP1) induces specific NFkappaB complexes in human T-lymphoid cells Virus Res. 67:17-30.
308. Baran-Marszak F., Fagard R., Girard B., Camilleri-Broet S., Zeng F., Lenoir G. M., Raphael M., and Feuillard J. 2002. Gene array identification of Epstein Barr virus-regulated cellular genes in EBV-converted Burkitt lymphoma cell lines Lab Invest. 82:1463-79.
309. Roan F., Inoue N., and Offermann M. K. 2002. Activation of cellular and heterologous promoters by the human herpesvirus 8 replication and transcription activator Virology. 301:293-304.
310. Collot S., Petit B., Bordessoule D., Alain S., Touati M., Denis F., and Ranger-Rogez S. 2002. Real-time PCR for quantification of human herpesvirus 6 DNA from lymph nodes and saliva J Clin Microbiol. 40:2445-51.
311. Kao C. C., Yew P. R., and Berk A. J. 1990. Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55K proteins Virology. 179:806-14.
312. Dobner T., Horikoshi N., Rubenwolf S., and Shenk T. 1996. Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor Science. 272:1470-3.
313. Steegenga W. T., Riteco N., Jochemsen A. G., Fallaux F. J., and Bos J. L. 1998. The large E1B protein together with the E4orf6 protein target p53 for active degradation in adenovirus infected cells Oncogene. 16:349-57.
314. Bargonetti J., Reynisdottir I., Friedman P. N., and Prives C. 1992. Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53 Genes Dev. 6:1886-98.
315. Sheppard H. M., Corneillie S. I., Espiritu C., Gatti A., and Liu X. 1999. New insights into the mechanism of inhibition of p53 by simian virus 40 large T antigen Mol Cell Biol. 19:2746-53.
316. Thomas M., Massimi P., Jenkins J., and Banks L. 1995. HPV-18 E6 mediated inhibition of p53 DNA binding activity is independent of E6 induced degradation Oncogene. 10:261-8.
317. Scheffner M., Werness B. A., Huibregtse J. M., Levine A. J., and Howley P. M. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 Cell. 63:1129-36.
318. Elmore L. W., Hancock A. R., Chang S. F., Wang X. W., Chang S., Callahan C. P., Geller D. A., Will H., and Harris C. C. 1997. Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis Proc Natl Acad Sci U S A. 94:14707-12.
319. Prost S., Ford J. M., Taylor C., Doig J., and Harrison D. J. 1998. Hepatitis B x protein inhibits p53-dependent DNA repair in primary mouse hepatocytes J Biol Chem. 273:33327-32.
320. Kwon J. A., and Rho H. M. 2003. Transcriptional repression of the human p53 gene by hepatitis B viral core protein (HBc) in human liver cells Biol Chem. 384:203-12.
321. Bonin L. R., and McDougall J. K. 1997. Human cytomegalovirus IE2 86-kilodalton protein binds p53 but does not abrogate G1 checkpoint function J Virol. 71:5861-70.
322. Slebos R. J., Lee M. H., Plunkett B. S., Kessis T. D., Williams B. O., Jacks T., Hedrick L., Kastan M. B., and Cho K. R. 1994. p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein Proc Natl Acad Sci U S A. 91:5320-4.
323. Jones D. L., Alani R. M., and Munger K. 1997. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2 Genes Dev. 11:2101-11.
324. DeCaprio J. A., Ludlow J. W., Figge J., Shew J. Y., Huang C. M., Lee W. H., Marsilio E., Paucha E., and Livingston D. M. 1988. SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene Cell. 54:275-83.
325. Sen R., and Baltimore D. 1986. Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism Cell. 47:921-8.
326. Wang J., Jones C., Norcross M., Bohnlein E., and Razzaque A. 1994. Identification and characterization of a human herpesvirus 6 gene segment capable of transactivating the human immunodeficiency virus type 1 long terminal repeat in an Sp1 binding site-dependent manner J Virol. 68:1706-13.